Currently Viewing:
Newsroom
Currently Reading
Insomnia Correlated to an Increased Risk of Heart Disease and Stroke, Study Shows
August 19, 2019 – Matthew Gavidia
Inspiratory Muscle Training May Be an Option for Patients Who Decline Pulmonary Rehabilitation for COPD
August 18, 2019 – Kelly Davio
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez

Dova Pharmaceuticals Launching Avatrombopag for Chronic Immune Thrombocytopenia

Alison Rodriguez
With the FDA approval of a supplemental New Drug Application (sNDA) expanding the use of avatrombopag (Doptelet) for patients with chronic immune thrombocytopenia (ITP), Dova Pharmaceuticals said recently it will begin marketing the drug for the new indication in the middle of July.
With the FDA approval of a supplemental New Drug Application (sNDA) expanding the use of avatrombopag (Doptelet) for patients with chronic immune thrombocytopenia (ITP), Dova Pharmaceuticals said recently it will begin marketing the drug for the new indication in the middle of July.

The approval of avatrombopag is intended for adult patients with ITP who did not have a significant response to a previous treatment as well as adult patients with chronic liver disease who are undergoing a procedure. Also, the new treatment is administered orally and therefore limits strict dietary restrictions for patients.

“Dova is pleased to provide Doptelet to patients and physicians in the United States for the treatment of chronic ITP in adult patients who have had an insufficient response to a previous treatment,” David Zaccardelli, PharmD, Dova’s president and chief executive officer, stated. “In addition to offering patients with ITP a new treatment option, we expect DOPTELET will also address an important unmet medical need in the market.”

The phase 3 study results lead to the approval. Those on the new drug had platelet counts of at least 50,000 per µL at day 8 of treatment. Furthermore, throughout the 6-month treatment period, avatrombopag was found to be more effective than the placebo in maintaining platelet counts. This data, along with the 24 other studies in the avatrombopag clinical development program, demonstrated the safety and efficacy of the treatment.

“ITP patients should work with their clinician to choose a therapy that supports their lifestyle and aims to achieve the best possible result to treat their ITP. That’s why having additional treatment options are so important,” said Caroline Kruse, president and chief executive officer of the Platelet Disorder Support Association. “We are thrilled to have a new, oral TPO-RA available for adult patients with ITP.  Every new treatment provides more choices and new hope to our community.”

In the future Zaccardelli anticipates that avatrombopag may also be effective in treating chemotherapy-induced thrombocytopenia, as phase 3 trial results will be available in 2020.

Related Articles

Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia
Early Data Suggests CC-486 Relatively Safe, Effective in Thrombocytopenic Patients With MDS
Romiplostim Produces Durable Platelet Responses in Pediatric Patients with Immune Thrombocytopenia
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up